-- Catalyst Pharmaceuticals (CPRX) is being considered as a potential acquisition by Italy's Angelini Pharma, Bloomberg reported Monday, citing people familiar with the matter.
Angelini is working with advisers, and talks are at a preliminary stage with no certainty of a transaction, the sources said.
The Italian drugmaker is reviewing other possible targets, while Catalyst may attract interest from other suitors, the report said.
Catalyst and Angelini did not immediately reply to requests for comment from.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: $30.29, Change: $+2.92, Percent Change: +10.67%